Appendix B: Provincial Case Definitions for Diseases of Public Health Significance

Disease: Campylobacter enteritis

Effective: February 2019
Campylobacter enteritis

1.0 Provincial Reporting
Confirmed and probable cases of disease

2.0 Type of Surveillance
Case-by-case

3.0 Case Classification

3.1 Confirmed Case
Laboratory confirmation of Campylobacter spp. with or without clinically compatible signs and symptoms:
  • Isolation of Campylobacter spp. by culture from an appropriate clinical specimen (e.g. stool, urine, body fluids)

3.2 Probable Case
  • Clinically compatible signs and symptoms in a person with an epidemiologic link to a laboratory-confirmed case
    OR
  • Positive/detection of Campylobacter spp. by a nucleic acid amplification test (NAAT)
    • Laboratory Evidence

3.3 Laboratory Confirmation
The following will constitute a confirmed case of Campylobacteriosis:
  • Positive culture for Campylobacter spp.

3.4 Approved/Validated Tests
  • Standard culture for Campylobacter spp.
  • Nucleic acid amplification test (NAAT) (which includes polymerase chain reaction (PCR) and multiplex molecular tests) for Campylobacter spp.

3.5 Indications and Limitations
  • Further strain characterization is indicated for epidemiological, public health and control purposes
4.0 Clinical Evidence
Clinically compatible signs and symptoms are characterized by diarrhea, abdominal pain, malaise, fever, nausea, and/or vomiting

5.0 ICD 10 Code(s)
A04.5 Campylobacter enteritis

6.0 Sources


7.0 Document History
Table 1: History of Revisions

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Document Section</th>
<th>Description of Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 2014</td>
<td>General</td>
<td>New template.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 9.0 Document History added.</td>
</tr>
<tr>
<td>January 2014</td>
<td>3.1 Confirmed Case</td>
<td>Addition of second bullet point: “OR Detection of <em>Campylobacter</em> spp. by nucleic acid amplification testing (NAAT) from an appropriate clinical specimen (see above)”</td>
</tr>
<tr>
<td>January 2014</td>
<td>4.1 Laboratory Confirmation</td>
<td>Addition of second bullet point: “Positive nucleic acid amplification test (NAAT) assays for <em>Campylobacter</em> spp.”.</td>
</tr>
<tr>
<td>January 2014</td>
<td>4.2 Approved/ Validated Tests</td>
<td>Addition of second bullet point: “Nucleic acid amplification test (NAAT) assays for <em>Campylobacter</em> spp.”.</td>
</tr>
<tr>
<td>Revision Date</td>
<td>Document Section</td>
<td>Description of Revisions</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>January 2014</td>
<td>4.3 Indications and Limitations</td>
<td>Deletion of first bullet point: “Commercial nucleic acid amplification test (NAT) assays for <em>Campylobacter</em> spp. are presently not available”.</td>
</tr>
<tr>
<td>January 2014</td>
<td>8.0 Sources</td>
<td>Updated.</td>
</tr>
<tr>
<td>February 2019</td>
<td>General</td>
<td>Minor revisions were made to support the regulation change to Diseases of Public Health Significance. Detection of <em>Campylobacter</em> spp. by nucleic acid amplification testing (NAAT) from an appropriate clinical specimen was moved from a confirmed case to probable.</td>
</tr>
</tbody>
</table>